Takeaway
- Finerenone was associated with improved renal and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), irrespective of sodium/glucose cotransporter-2 inhibitor (SGLT2i) use at baseline.
Why this matters
- Patients with CKD and T2D often have an unmet treatment need despite SGLT2i treatment.
Study...